Survodutide
Also known as: BI 456906
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
Pricing for Survodutide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
Average price
$13.55/mg
range $7.80–$32.10/mg
Sellers
21
from $0.00
45-day trend
-29.3%
vs 45-day avg $/mg
16 of 21 sellers have a current price· 8 stale listings hidden (not seen in 7 days)
Top Merit pick
🇺🇸 Profound Aminos95via Disclosed Labs · just now
$9.92/mg -26.8% vs avg$119
12mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · just now
$10.00/mg -26.2% vs avg$99.99
10mg
no purity - 🇺🇸 Hydro Research Peptides91
via Disclosed Labs · just now
$12.00/mg -11.4% vs avg$720
60mg
- 🇺🇸 Peptidology89
✓ verified at source · just now
$8.00/mg -41% vs avg$79.99
10mg
- 🇺🇸 EZ Peptides85
✓ verified at source · just now
$7.80/mg -42.4% vs avg$78.00
10mg
99.4% purity 2 COAs - 🇺🇸 Certified Peptides62
✓ verified at source · just now
$10.00/mg -26.2% vs avg$100
10mg
no purity - 🇭🇰 zztai Peptide Ltd43
✓ verified at source · just now
$25.70/mg +89.7% vs avg$257
10mg
no purity - optimasupply.isUnscored
via Disclosed Labs · just now
$16.25/mg +19.9% vs avg$390
24mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
COAs for Survodutide
23 third-party tests across 5 vendors. Each card links to the full report.
For
Survodutide
by Profound Aminos· batch Yellow Cap
For
Survodutide
by Real Peptides· batch Clear Cap/Purple Crimp
For
Suvrodutide
by Kimera Chems· batch KC-SVD-BLK1
For
Survodutide
by Skye Peptides· batch SV25-12-001
For
Survodutide
by Ruo Bio· batch sur001
For
Survodutide
by Kimera Chems· batch KC-SVD-RED1
For
Survodutide
by Skye Peptides· batch SV25-06-001
For
Survodutide
by EZ Peptides· batch EZP-SURV1009082025-01
For
Survodutide
by EZ Peptides· batch EZP-SURV1009082025-01
For
Survodutide
by Profound Aminos· batch 2025-01-23
For
Survodutide
by Hydro Research Peptides· batch 2024-08-05
For
Survodutide
by Optima Supply· batch 2024-08-05
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
For
Survodutide
by Optima Supply· batch Survodutide-6033
For
Survodutide
by Peptidology· batch 1671
For
Suvrodutide
by Kimera Chems· batch KC-SVD-RED1
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
Purity not on file
For
Survodutide
by Ruo Bio
20 citations indexed for Survodutide
Study · 2026
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity
Aims This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.
Study · 2026
Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial
Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor (GLP-1R) dual agonist with the potential to induce greater weight reductions than GLP-1R mono-agonists.
review · 2026
How does survodutide work? Plain language review of a potential new medication for obesity and liver disease
What is this review about? This review provides an overview of a medication called survodutide. Survodutide is not yet approved for use but is currently being tested to treat people living with obesity , as well as those living with MASH (metabolic dysfunction-associated steatohepatitis).
Study · 2026
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treating obesity and related diseases.
Study · 2026
Survodutide Once Weekly for the Treatment of Adults with Obesity
Background Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.
Study · 2026
Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis
Background Metabolism-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide.